Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
about
sameAs
Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Advanced glycation end products and diabetic complicationsEffect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage.Diagnostic potential of plasma carboxymethyllysine and carboxyethyllysine in multiple sclerosisDifferential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin-treated, apolipoprotein E-deficient mice.The maillard reaction in eye diseases.In vitro antidiabetic and inhibitory potential of turmeric (Curcuma longa L) rhizome against cellular and LDL oxidation and angiotensin converting enzyme.AGEs breaking and antioxidant treatment improves endothelium-dependent dilation without effect on flow-mediated remodeling of resistance arteries in old Zucker diabetic rats.Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.Role of advanced glycation end products in cardiovascular disease.Agents in development for the treatment of diabetic nephropathy.Targeting AGEs Signaling Ameliorates Central Nervous System Diabetic Complications in RatsAdvanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling.RAGE and its ligands: a lasting memory in diabetic complications?Remodeling of the rat distal colon in diabetes: function and ultrastructure.Advanced glycation end products: Key players in skin aging?Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complicatCells and tissue interactions with glycated collagen and their relevance to delayed diabetic wound healingReduction of advanced-glycation end products levels and inhibition of RAGE signaling decreases rat vascular calcification induced by diabetes.The pathogenic role of Maillard reaction in the aging eye.Microvascular modifications in diabetic retinopathy.Naturally occurring inhibitors against the formation of advanced glycation end-products.Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β.Advanced glycation end products and diabetic retinopathy.Molecular basis of arterial stiffening: role of glycation - a mini-review.Glycated proteome: from reaction to intervention.The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.Optic nerve head biomechanics in aging and diseaseAged garlic has more potent antiglycation and antioxidant properties compared to fresh garlic extract in vitro.Impact of Non-Enzymatic Glycation in Neurodegenerative Diseases: Role of Natural Products in Prevention.Antioxidants reverse age-related collateral growth impairment.Below the radar: advanced glycation end products that detour "around the side". Is HbA1c not an accurate enough predictor of long term progression and glycaemic control in diabetes?Neuronal cell death and regeneration in diseases associated with advanced glycation end-products accumulation.Aminoguanidine partially prevents the reduction in liver pyruvate kinase activity in diabetic rats.Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs)-induced apoptosis.Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death.Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways.Trehalose and 6-aminohexanoic acid stabilize and renature glucose-6-phosphate dehydrogenase inactivated by glycation and by guanidinium hydrochloride.Enzymic and non-enzymic cross-linking mechanisms in relation to turnover of collagen: relevance to aging and exercise.C16, a novel advanced glycation endproduct breaker, restores cardiovascular dysfunction in experimental diabetic rats.
P2860
Q27007027-3888803D-5B42-44AB-B14C-D2885912EAF0Q27687501-E4CD07E6-CF70-4BF1-90C0-AE2575807EFCQ33623472-2467C395-5608-4BB8-9AB7-7DF19275C7ADQ34321561-A4E62D9C-0A29-482E-B750-4E6C8DAB8F4FQ34399952-2C724572-1A03-4089-A0E4-447DEB137684Q34436018-CA90791A-5637-448D-B865-308AEB4DBE52Q34614074-78D9D04E-5C9A-47BE-BAE0-153677C6F181Q35104846-99615A6C-1152-41A5-8FD5-DDCA76CD039CQ35546284-6D7EBC16-64AC-43C4-8BBA-AB7D3D228F1EQ35929112-2FBF2449-1C14-431A-9FD7-CFB5D5CC3E6BQ36099419-88126889-5961-4E55-80A3-76085C8451D4Q36154554-184B15FA-5C2E-4E37-AC80-D325B2707967Q36193769-94F1FAFD-1054-4BD1-9447-83CE7585C81EQ36320548-46605493-DE31-48D9-8158-D5B54759A7C7Q36480308-EDDD21CB-8F80-41AB-94F0-8AE739EE58E7Q36643573-AA34D24E-8A61-4EFB-A781-377BE2BDA230Q37054987-2D78438B-31E5-41B7-A646-EC06E251673AQ37157673-C220513B-926C-4A74-A2F9-13B025173B9AQ37499860-F8A43F39-AB6F-4B68-8F3F-6F10E4700791Q37801857-B5AD391A-480E-4A57-B377-3289F122866FQ37879581-D565B472-C3D3-4FF4-B5F8-05C1D4262ABBQ37903708-F58804E6-C07C-4CAE-9253-4BCFF60C54A4Q37924999-EE6A9BB8-F779-44A4-B2A6-5D1593834D49Q37930514-A7085256-CAF3-4CE2-8DC4-3A6FE1A236BFQ37973610-7706E096-465F-42EE-AB57-D77C3BD08C7EQ38062900-670D5F72-47B9-400C-8EC3-869672A7E6E3Q38394355-A46B678B-2B22-42FC-B7D0-5CB6176502BCQ38394783-BE20CC31-EA39-4BC5-8B3C-7583184E19FDQ38775025-B4E9EBEC-48EF-47D3-A53C-08D26A3F82E4Q39368611-DBA576C7-B481-4CDA-A1A3-048D0FA02FE1Q40055510-18B692E3-C7B6-451B-B73A-F07F9087ED7DQ40802125-DC174969-18CB-41B3-8A8C-5ECB1D35C48CQ41863955-6CDE5562-9647-4A6A-86DF-2B1648E8EFB6Q42010611-F002CEF4-1226-469B-B66E-4968DF93A7DDQ43108062-05E0867F-96B3-49A8-9BA4-E83AB578AC04Q43951595-D340054C-E3E5-4DD4-82B4-7EE534CAE1D5Q45182285-9ADAC685-FEFA-47C9-8E8F-605176EE9579Q46447820-25FB0D8D-F905-4F53-BDAD-A4AB650DB3A1Q46584500-D7A00817-F736-4E89-AE44-457EA2132D32Q46811176-A83471B1-BF42-4154-A83E-3BE8A603FEFB
P2860
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@ast
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@en
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@nl
type
label
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@ast
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@en
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@nl
prefLabel
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@ast
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@en
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@nl
P2093
P1476
Therapeutic potential of breakers of advanced glycation end product-protein crosslinks
@en
P2093
Hank Founds
Peter Foiles
Sara Vasan
P356
10.1016/J.ABB.2003.08.016
P407
P577
2003-11-01T00:00:00Z